GlassScriptPhysician profile
Edgar M Levine
NPI 1679537674
$2,845.96
in general payments reported to CMS, 2019-2025
26 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $298 · 2021: $153 · 2022: $561 · 2023: $403 · 2024: $293 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $872.25 | 2019-2025 | Clareon, Clareon Panoptix Pro, Wavelight Refractive Suite |
| Ocular Therapeutix, INC. | $488.58 | 2019-2025 | Dextenza |
| Glaukos Corporation | $208.96 | 2025 | Idosetr, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Allergan, INC. | $172.82 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $144.49 | 2022-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Biotissue Holdings INC. | $120.65 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $119.65 | 2023-2025 | Envista Envy Iol, Miebo, Xiidra |
| Sight Sciences, INC. | $113.57 | 2019-2024 | Omni Surgical System |
| Oyster Point Pharma, INC. | $98.32 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $90.37 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.99 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $39.32 | 2019 | |
| Sun Pharmaceutical Industries INC. | $37.06 | 2023 | Cequa |
| Thea Pharma INC. | $24.79 | 2025 | Iyuzeh |
| Oasis Medical, INC. | $24.27 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.91 | 2023 | Acthar |
| Eyevance Pharmaceuticals LLC | $23.40 | 2022 | |
| Aerie Pharmaceuticals, INC. | $21.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.46 | 2020 | |
| Amgen INC. | $20.84 | 2025 | Tepezza |
| Harrow Eye, LLC | $19.19 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $18.11 | 2019 | |
| Eyepoint US, INC. | $17.88 | 2019 | |
| Abbvie INC. | $15.47 | 2024 | |
| Quidel Corporation | $15.13 | 2023 | |
| Carl Zeiss Meditec, INC. | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.